ethyl 3-oxo-2-<<2-(trifluoromethyl)phenyl>methylene>butanoate | 114957-75-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: ethyl 3-oxo-2-<<2-(trifluoromethyl)phenyl>methylene>butanoate
• 英文别名: 2-[[2-(trifluoromethyl)phenyl]methylene]-3-oxobutanoic acid,ethyl ester；2'-trifluoromethylbenzylideneacetoacetic acid ethyl ester；ethyl (2Z)-3-oxo-2-[[2-(trifluoromethyl)phenyl]methylidene]butanoate
• CAS: 114957-75-4
• 化学式: C₁₄H₁₃F₃O₃
• 分子量: 286.251
• InChiKey: SLKLZDHEMCXMNH-FLIBITNWSA-N

物化性质

• 沸点：
  263.8±40.0 °C(predicted)
• 密度：
  1.242±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl 3-oxo-2-<<2-(trifluoromethyl)phenyl>methylene>butanoate 在 盐酸 、 碳酸氢钠 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 6-甲基-2-氧代-4-[2-(三氟甲基)苯基]-1,2,3,4-四氢嘧啶-5-羧酸乙酯
  参考文献：
  名称：

  O'Reilly, Brian C.; Atwal, Karnail S., Heterocycles, 1987, vol. 26, # 5, p. 1185 - 1188

  摘要：

  DOI：

文献信息

• 2-thio or oxo-4-aryl or heterocyclo-1,5(2H)-pyrimidinedicarboxylic acid
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US05202330A1

  公开（公告）日：1993-04-13

  Pyrimidine compounds of the formula ##STR1## wherein X is sulfur or oxygen, Y is R.sub.11 or --O--R.sub.1, and R.sub.4 is aryl or heterocyclo are disclosed. These compounds are useful as cardiovascular agents, particularly anti-hypertensive agents, due to their calcium entry blocking vasodilator activity.

  公开了符合以下公式的嘧啶化合物##STR1##其中X是硫或氧，Y是R.sub.11或--O--R.sub.1，R.sub.4是芳香族或杂环。这些化合物由于其钙通道阻滞血管扩张剂活性而被用作心血管药物，特别是抗高血压药物。
• 1,2,3,4-Tetrahydro-6-substituted-4-aryl(or heterocyclo)-3-((substituted
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US04855301A1

  公开（公告）日：1989-08-08

  Cardiovascular activity is exhibited by compounds having the formula ##STR1## and pharmaceutically acceptable salts thereof wherein X is oxygen or sulfur; R is hydrogen, alkyl, cycloalkyl, aryl, or arylalkyl and R.sub.1 is hydrogen, alkyl, cycloalkyl, aryl, heterocyclo, ##STR2## or halo substituted alkyl, or R and R.sub.1 taken together with the nitrogen atom to which they are attached are 1-pyrrolidinyl, 1-piperidinyl, 1-azepinyl, 4-morpholinyl, 4-thiamorpholinyl, 1-piperazinyl, 4-alkyl-1-piperazinyl, 4-arylalkyl-1-piperazinyl, 4-diarylalkyl-1-piperazinyl or 1-pyrrolidinyl, 1-piperidinyl, or 1-azeipinyl substituted with alkyl, alkoxy, alkylthio, halo, trifluoromethyl or hydroxy; R.sub.2 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, ##STR3## or halo substituted alkyl; R.sub.3 is hydrogen, alkyl, cycloalkyl, aryl, heterocyclo, ##STR4## or halo substituted alkyl; R.sub.4 is aryl or heterocyclo; R.sub.5 and R.sub.6 are each independently hydrogen, alkyl, --(CH.sub.2).sub.q --aryl or --(CH.sub.2).sub.q --cycloalkyl; Y.sub.1 is cycloalkyl, aryl, heterocyclo, hydroxyl, alkoxy, aryl--(CH.sub.2).sub.m --O--, mercapto, alkylthio, aryl--(CH.sub.2).sub.m --S--, amino, substituted amino, carbamoyl, ##STR5## Y.sub.3 is hydroxyl, alkoxy, aryl--(CH.sub.2).sub.m --O--, mercapto, alkylthio, aryl--(CH.sub.2).sub.m --S--, ##STR6## amino, or substituted amino; q is 0, 1, 2 or 3; m is 0 or an integer of 1 to 6; n is 0 or an integer of 1 to 5; and p is an integer of 1 to 5.

  心血管活性化合物具有以下通式： ##STR1## 及其药学上可接受的盐，其中X为氧或硫；R为氢、烷基、环烷基、芳基或芳基烷基，R1为氢、烷基、环烷基、芳基、杂环、##STR2##或卤代烷基，或者R和R1与其所连接的氮原子一起形成1-吡咯烷基、1-哌啶基、1-氮杂环庚三烯基、4-吗啉基、4-硫吗啉基、1-哌嗪基、4-烷基-1-哌嗪基、4-芳基烷基-1-哌嗪基、4-二芳基烷基-1-哌嗪基或1-吡咯烷基、1-哌啶基、或1-氮杂环庚三烯基，这些基团可以被烷基、烷氧基、烷硫基、卤素、三氟甲基或羟基取代；R2为氢、烷基、烯基、炔基、环烷基、芳基、##STR3##或卤代烷基；R3为氢、烷基、环烷基、芳基、杂环、##STR4##或卤代烷基；R4为芳基或杂环；R5和R6各自独立为氢、烷基、--(CH2)q--芳基或--(CH2)q--环烷基；Y1为环烷基、芳基、杂环、羟基、烷氧基、芳基--(CH2)m--O--、巯基、烷硫基、芳基--(CH2)m--S--、氨基、取代氨基、氨基甲酰基、##STR5##Y3为羟基、烷氧基、芳基--(CH2)m--O--、巯基、烷硫基、芳基--(CH2)m--S--、##STR6##氨基或取代氨基；q为0、1、2或3；m为0或1至6的整数；n为0或1至5的整数；p为1至5的整数。
• 2-Amino-1,4-dihydropyridine derivatives
  申请人：Bayer Aktiengesellschaft

  公开号：US03935223A1

  公开（公告）日：1976-01-27

  2-Amino-1,4-dihydropyridines bearing a carbonyl function in the 5-position and being optionally substituted by lower alkyl or phenyl in the 6-position, and the corresponding 2-amino-1,4,5,6,7,8-hexahydro-5-oxoquinolines, which derivatives are further substituted by a carbonyl group in the 3-position and optionally substituted in the 4-position by lower alkyl, phenyl, substituted phenyl or a heterocyclic group are anti-hypertensive agents and coronary vessel dilators. The compounds, of which 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3,5-diethyl ester is a representative embodiment, are prepared through condensation of an ylideneacetoacetic acid ester and an amidine.

  5位带有羰基功能的2-氨基-1,4-二氢吡啶，可选择在6位被较低的烷基或苯基取代，以及相应的2-氨基-1,4,5,6,7,8-六氢-5-酮喹啉，这些衍生物在3位进一步被羰基取代，并可选择在4位被较低的烷基、苯基、取代苯基或杂环基取代，是抗高血压药物和冠状血管扩张剂。这些化合物，其中2-氨基-6-甲基-4-(3-硝基苯基)-1,4-二氢吡啶-3,5-二羧酸3,5-二乙酯是一个代表性实施例，通过乙二酰丙酸酯和胺基甲酸酰基的缩合制备。
• Tetrahydroimidazolo[1,2-a]pyridine derivatives
  申请人：Bayer Aktiengesellschaft

  公开号：US03935220A1

  公开（公告）日：1976-01-27

  1,4-Dihydropyridines bearing carbonyl functions in the 3- and 5-positions, being optionally substituted by lower alkyl in the 6-position, being substituted in the 4-position by lower alkyl, phenyl, substituted phenyl or a heterocyclic group, and being fused through the 1- and 2-positions to a five, six or seven membered cycloalkyl ring, one methylene group of which can be replaced by sulfur, oxygen imino or alkylimino, are antihypertensive agents and coronary vessel dilators. The compounds, of which 6-methyl-4-(3-nitrophenyl)-1,2-pentamethylene-1,4-dihydropyridine-3,5-dica rboxylic acid 3,5-diethyl ester is a representative embodiment, are prepared through condensation of an ylideneacetoacetic acid ester and a cyclic enamino carbonyl derivative.

  在3和5位带有羰基功能的1,4-二氢吡啶，可以在6位上选择性地被低碳基取代，在4位被低碳基，苯基，取代苯基或杂环基所取代，并通过1和2位与五，六或七元环烷基环融合，在其中一个亚甲基可以被硫，氧，亚胺或烷基亚胺取代，是抗高血压药和冠状血管扩张剂。这些化合物，其中6-甲基-4-(3-硝基苯基)-1,2-戊亚甲基-1,4-二氢吡啶-3,5-二羧酸3,5-二乙酯是一个代表性实施例，通过一个亚甲基乙酮酸酯和一个环状烯胺羰基衍生物的缩合制备。
• 2-Amino-4,5-dihydropyridine derivatives
  申请人：Bayer Aktiengesellschaft

  公开号：US03959292A1

  公开（公告）日：1976-05-25

  4,5-Dihydropyridines bearing an N,N-disubstituted amino group in the 2-position, carbonyl functions in the 3- and 5-positions and being optionally substituted in the 6-position by lower alkyl or phenyl and, in the 4-position by lower alkyl, phenyl, substituted phenyl or a heterocyclic group, are antihypertensive agents and coronary vessel dilators. The compounds, of which 2-pyrrolidino-6-methyl-4-(3-nitrophenyl)-4,5-dihydropyridine-3,5-dicarboxy lic acid 3,5-diethyl ester is a representative embodiment, are prepared through condensation of an ylideneacetoacetic acid ester and a substituted 3,3-diaminoacrylate.

  具有N,N-二取代氨基基团的4,5-二氢吡啶，3-和5-位上带有羰基功能，6-位上可选地被低碳链或苯基取代，4-位上被低碳链、苯基、取代苯基或杂环基取代，是降压剂和冠状血管扩张剂。这些化合物，其中2-吡咯烷基-6-甲基-4-(3-硝基苯基)-4,5-二氢吡啶-3,5-二羧酸3,5-二乙酯是代表性实施例，是通过一个亚甲基乙酰乙酸酯和一个取代的3,3-二氨基丙烯酸酯的缩合反应制备的。